Management of infusion reactions in clinical trials and beyond: the US and EU perspectives

Cmelak, Anthony J; Lordick, Florian; Borner, Markus; Goldberg, Richard M; Saif, M Wasif (2009). Management of infusion reactions in clinical trials and beyond: the US and EU perspectives. Oncology, 23(2 Suppl 1), pp. 18-25. Norwalk, Conn.: UBM Medica

Full text not available from this repository. (Request a copy)

Monoclonal antibodies have expanded our cancer-fighting armamentarium in both the United States and Europe. While in general, monoclonal antibodies are well tolerated and do not have significant overlapping side effects with traditional cytotoxic agents, severe infusion reactions (IRs)--sometimes severe enough to be life threatening--have been reported. The pathophysiology of severe infusion reactions associated with monoclonal antibodies is poorly understood, but mechanisms are beginning to be elucidated. Geographic differences in the incidence of IRs have become apparent. Understanding the risk, recognizing the signs and symptoms, and being ready to promptly manage severe IRs are key for the clinician to avoid unnecessarily discontinuing these effective anticancer agents and prevent potentially tragic consequences for their patients. To date, clinical trials have incorporated monoclonal antibodies into combinations with standard cytotoxic regimens; it is expected that in time clinical trials will be testing promising new combinations utilizing multiple targeted agents, resulting in improved toxicity profiles and efficacy for cancer patients.

Item Type:

Journal Article (Further Contribution)


04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Borner, Markus




UBM Medica




Factscience Import

Date Deposited:

04 Oct 2013 15:11

Last Modified:

17 Mar 2015 22:30

PubMed ID:


Web of Science ID:


URI: (FactScience: 195864)

Actions (login required)

Edit item Edit item
Provide Feedback